Immune‐related adverse events and outcomes among pan‐cancer patients receiving immune checkpoint inhibitors: A monocentric real‐world observational study

BACKGROUND: Real‐world evidence on immune‐related adverse events (irAEs) are relatively insufficient. Herein patterns and outcomes of irAEs after administration of anti‐programmed cell death 1 (PD‐1) and its legend 1 (PD‐L1) antibodies were investigated. METHODS: Patients treated with anti‐PD‐1/PD‐L...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Xiaoxiao, Jiang, Weiping, Li, Hongqing, Wu, Yanxu, Li, Xiangyang, Cui, Shaohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557884/
https://www.ncbi.nlm.nih.gov/pubmed/37564011
http://dx.doi.org/10.1002/cam4.6449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557884/
https://www.ncbi.nlm.nih.gov/pubmed/37564011
http://dx.doi.org/10.1002/cam4.6449

Ejemplares similares